- Home
- KINS vs CDXS Comparison
KINS vs CDXS Comparison
Compare KINS & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- CDXS
- Stock Information
- Founded
- KINS 1886
- CDXS 2002
- Country
- KINS United States
- CDXS United States
- Employees
- KINS N/A
- CDXS N/A
- Industry
- KINS Property-Casualty Insurers
- CDXS Major Chemicals
- Sector
- KINS Finance
- CDXS Industrials
- Exchange
- KINS Nasdaq
- CDXS Nasdaq
- Market Cap
- KINS 251.5M
- CDXS 201.3M
- IPO Year
- KINS N/A
- CDXS 2010
- Fundamental
- Price
- KINS $16.30
- CDXS $2.30
- Analyst Decision
- KINS Strong Buy
- CDXS Buy
- Analyst Count
- KINS 1
- CDXS 2
- Target Price
- KINS $6.50
- CDXS $11.00
- AVG Volume (30 Days)
- KINS 428.3K
- CDXS 1.0M
- Earning Date
- KINS 05-08-2025
- CDXS 05-14-2025
- Dividend Yield
- KINS N/A
- CDXS N/A
- EPS Growth
- KINS 5417.04
- CDXS N/A
- EPS
- KINS 1.60
- CDXS N/A
- Revenue
- KINS $169,875,701.00
- CDXS $49,815,000.00
- Revenue This Year
- KINS $40.63
- CDXS $2.41
- Revenue Next Year
- KINS $6.92
- CDXS $34.28
- P/E Ratio
- KINS $10.21
- CDXS N/A
- Revenue Growth
- KINS 18.52
- CDXS N/A
- 52 Week Low
- KINS $4.55
- CDXS $1.90
- 52 Week High
- KINS $22.40
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- KINS 45.69
- CDXS 44.61
- Support Level
- KINS $15.63
- CDXS $2.30
- Resistance Level
- KINS $17.54
- CDXS $2.56
- Average True Range (ATR)
- KINS 1.09
- CDXS 0.20
- MACD
- KINS -0.18
- CDXS -0.01
- Stochastic Oscillator
- KINS 9.90
- CDXS 46.67
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.